Ampio Pharmaceuticals (AMPE) Competitors $0.0027 0.00 (0.00%) As of 08/22/2025 01:48 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AMPE vs. EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, PXMD, CALA, CLVR, and EFTRShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), PaxMedica (PXMD), Calithera Biosciences (CALA), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Its Competitors Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma PaxMedica Calithera Biosciences Clever Leaves eFFECTOR Therapeutics Ampio Pharmaceuticals (NYSE:AMPE) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations. Which has more volatility & risk, AMPE or EVLO? Ampio Pharmaceuticals has a beta of 4.69, indicating that its stock price is 369% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Is AMPE or EVLO more profitable? Company Net Margins Return on Equity Return on Assets Ampio PharmaceuticalsN/A N/A N/A Evelo Biosciences N/A N/A N/A Does the media prefer AMPE or EVLO? In the previous week, Evelo Biosciences had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score. Company Overall Sentiment Ampio Pharmaceuticals Neutral Evelo Biosciences Neutral Which has stronger valuation and earnings, AMPE or EVLO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00Evelo BiosciencesN/AN/A-$114.53MN/AN/A Do institutionals & insiders hold more shares of AMPE or EVLO? 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAmpio Pharmaceuticals beats Evelo Biosciences on 4 of the 5 factors compared between the two stocks. Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3K$832.56M$5.76B$20.92BDividend YieldN/A4.84%4.41%3.58%P/E Ratio0.001.1731.1029.13Price / SalesN/A26.34435.0353.00Price / CashN/A19.5637.7323.54Price / Book0.006.659.535.45Net Income-$8.63M-$4.94M$3.26B$992.10M7 Day PerformanceN/A1.08%2.10%2.61%1 Month PerformanceN/A2.03%2.82%1.46%1 Year PerformanceN/A10.56%30.56%10.72% Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+3.8%$3KN/A0.0020High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A+400.0%$9KN/A0.00120Options VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002News CoverageGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5KN/A0.0030Gap UpHigh Trading VolumeSTABStatera BiopharmaN/A$0.00flatN/A-66.7%$5KN/A0.0020PXMDPaxMedicaN/A$0.00flatN/AN/A$2KN/A0.002CALACalithera Biosciences0.6238 of 5 stars$0.00-80.0%N/A-98.4%$1KN/A0.0060CLVRClever LeavesN/A$0.00+50.0%N/AN/A$1K$17.42M0.00560Gap UpEFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.6%$1KN/A0.0010 Related Companies and Tools Related Companies Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors PaxMedica Competitors Calithera Biosciences Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access